Clinical Takeaway
A randomized controlled trial tested the Minder mobile app, co-developed with university students, to address mental health and substance use concerns during the high-risk college transition period. Digital tools like this are being evaluated as scalable, accessible options for reaching students who may not seek traditional care. Results from this trial offer evidence-based guidance on whether app-based interventions can meaningfully move the needle on mental health and substance use outcomes in this population.
#4 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.
Citation: Vereschagin Melissa et al.. Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.. Journal of medical Internet research. 2024. PMID: 38536225.
Design: 5 Journal: 0 N: 3 Recency: 1 Pop: 2 Human: 1 Risk: 0
This randomized controlled trial provides evidence on whether scalable digital interventions can effectively address the converging mental health and substance use challenges that emerge during the critical university transition period. The findings are clinically significant because they demonstrate whether a student-codeveloped mobile app can deliver measurable improvements in outcomes, potentially informing institutional adoption and reducing barriers to care through technology-enabled accessibility. If efficacious, this intervention model could establish a replicable framework for delivering integrated mental health and substance use support to a high-risk population with limited access to traditional clinical services.
Abstract: BACKGROUND: University attendance represents a transition period for students that often coincides with the emergence of mental health and substance use challenges. Digital interventions have been identified as a promising means of supporting students due to their scalability, adaptability, and acceptability. Minder is a mental health and substance use mobile app that was codeveloped with university students. OBJECTIVE: This study aims to examine the effectiveness of the Minder mobile app in improving mental health and substance use outcomes in a general population of university students. METHODS: A 2-arm, parallel-assignment, single-blinded, 30-day randomized controlled trial was used to evaluate Minder using intention-to-treat analysis. In total, 1489 participants were recruited and randomly assigned to the intervention (n=743, 49.9%) or waitlist control (n=746, 50.1%) condition. The Minder app delivers evidence-based content through an automated chatbot and connects participants with services and university social groups. Participants are also assigned a trained peer coach to support them. The primary outcomes were measured through in-app self-assessments and included changes in general anxiety symptomology, depressive symptomology, and alcohol consumption risk measured using the 7-item General Anxiety Disorder scale, 9-item Patient Health Questionnaire, and US Alcohol Use Disorders Identification Test-Consumption Scale, respectively, from baseline to 30-day follow-up. Secondary outcomes included measures related to changes in the frequency of substance use (cannabis, alcohol, opioids, and nonmedical stimulants) and mental well-being. Generalized linear mixed-effects models were used to examine each outcome. RESULTS: In total, 79.3% (589/743) of participants in the intervention group and 83% (619/746) of participants in the control group completed the follow-up survey. The intervention group had significantly greater average reductions in anxiety symptoms measure
🧠 This randomized controlled trial evaluates a student-developed mobile app for mental health and substance use support during a high-risk transitional period, which addresses a genuine gap in accessible campus interventions. The study’s strength lies in its focus on real-world digital delivery and codevelopment with the target population, factors that often improve engagement and relevance compared to top-down clinical tools. However, clinicians should note that the abstract provides limited detail on primary outcomes, effect sizes, duration of follow-up, and whether benefits persisted beyond the intervention period, making it difficult to assess clinical significance or sustainability. The university population also represents a relatively health-literate, often higher socioeconomic demographic, which may limit generalizability to broader or more medically complex patient populations we serve in primary care. For cannabis-using students specifically, consider whether the app adequately addresses substance-specific harms and motivational readiness, and whether it complements rather than substitutes for direct clinical assessment of use patterns and underlying psychiatric comorbidity.